Abidipharma
برای بیماران Abidi Diabetes Club logo-abidi
Languages
  • English
  • فارسی
  • GUIDELINES
  • SCIENTIFIC ARTICLES
  • CONTACT US
    Diabetes Club
    • GUIDELINES
    • SCIENTIFIC ARTICLES
    • CONTACT US

    Archives

    Author Archive for: "sisarv"
    Home » Archives for sisarv
    The effect of initial therapy with the fixed-dose combination of sitagliptin and metformin compared with metformin monotherapy in patients with type 2 diabetes mellitus
    By sisarv
    In Uncategorized
    Posted July 24, 2018

    The effect of initial therapy with the fixed-dose combination of sitagliptin and metformin compared with metformin monotherapy in patients with type 2 diabetes mellitus

    READ MORE
    Sitagliptin: A Review of Its Use in Patients with Type 2 Diabetes Mellitus
    By sisarv
    In Uncategorized
    Posted July 24, 2018

    Sitagliptin: A Review of Its Use in Patients with Type 2 Diabetes Mellitus

    READ MORE
    Research article Safety and tolerability of sitagliptin in clinical studies: a pooled analysis of data from 10,246 patients with type 2 diabetes
    By sisarv
    In Uncategorized
    Posted July 24, 2018

    Research article Safety and tolerability of sitagliptin in clinical studies: a pooled analysis of data from 10,246 patients with type 2 diabetes

    READ MORE
    Incretin treatment and risk of pancreatitis in patients with type 2 diabetes mellitus: systematic review and meta-analysis of randomised and non-randomised studies
    By sisarv
    In Uncategorized
    Posted July 24, 2018

    Incretin treatment and risk of pancreatitis in patients with type 2 diabetes mellitus: systematic review and meta-analysis of randomised and non-randomised studies

    READ MORE
    Efficacy and Safety of the Dipeptidyl Peptidase-4 Inhibitor Sitagliptin Added to Ongoing Metformin Therapy in Patients With Type 2 Diabetes Inadequately Controlled With Metformin Alone
    By sisarv
    In Uncategorized
    Posted July 24, 2018

    Efficacy and Safety of the Dipeptidyl Peptidase-4 Inhibitor Sitagliptin Added to Ongoing Metformin Therapy in Patients With Type 2 Diabetes Inadequately Controlled With Metformin Alone

    READ MORE
    Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double-blind, non-inferiority trial
    By sisarv
    In Uncategorized
    Posted July 24, 2018

    Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double-blind, non-inferiority trial

    READ MORE
    Efficacy and safety of sitagliptin when added to insulin therapy in patients with type 2 diabetes
    By sisarv
    In Uncategorized
    Posted July 24, 2018

    Efficacy and safety of sitagliptin when added to insulin therapy in patients with type 2 diabetes

    READ MORE
    Efficacy and safety of sitagliptin and metformin as initial combination therapy and as monotherapy over 2 years in patients with type 2 diabetes
    By sisarv
    In Uncategorized
    Posted July 24, 2018

    Efficacy and safety of sitagliptin and metformin as initial combination therapy and as monotherapy over 2 years in patients with type 2 diabetes

    READ MORE
    Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes
    By sisarv
    In Uncategorized
    Posted July 24, 2018

    Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes

    READ MORE
    Effect of Initial Combination Therapy With Sitagliptin, a Dipeptidyl Peptidase-4 Inhibitor, and Metformin on Glycemic Control in Patients With Type 2 Diabetes
    By sisarv
    In Ziptin - Zipmet, Ziptin - Zipmet, Ziptin - Zipmet, Ziptin - Zipmet, Ziptin - Zipmet, Ziptin - Zipmet, Ziptin - Zipmet, Ziptin - Zipmet, Ziptin - Zipmet, Ziptin - Zipmet
    Posted July 24, 2018

    Effect of Initial Combination Therapy With Sitagliptin, a Dipeptidyl Peptidase-4 Inhibitor, and Metformin on Glycemic Control in Patients With Type 2 Diabetes

    READ MORE
    Load More
    Searching

    phone: (+9821) 44522451

    Fax: (+9821) 44504787


    Address: NO,72,Abidi Blvd,8th Km of Lashgari Exp, Tehran, Iran


    Dr.Abidi Pharmaceutical

    www.abidipharma.ir

    Cobel Darou

    www.cobeldarou.com

    Diabetes Club

    The Abidi’s diabetes club was constituted on 11 June 2015 in Tehran for constant updating doctors knowledge who are engaged with treatment of diabetes, with support of expertise group consist of endocrinology professors of university of Tehran, Shahid Beheshti university and other universities of Iran and since then 40 class in variety cities of Iran has been conducted.

    About
    The number of people with diabetes in Iran is estimated by the IDF to be 5 million which just half of them have been diagnosed. Diabetes can cause serious complications, such as cardiovascular disease & renal failure. The major aim of the diabetic department of Dr. Abidi Pharmaceutical is to present a feasible solution to manage patients who have Type 2 diabetes.
    2018-2019 © Copyright abidipharma.ir
    Abidi Diabetes Club